The federal judge overseeing the Xarelto MDL (multidistrict litigation) concerning claims of severe bleeding problems occurring while taking Xarelto ordered that all new Xarelto lawsuits across the country be filed directly into his Louisiana courtroom.

Court records show that U.S. District Judge Eldon E. Fallon, who is managing the Xarelto side effects litigation in the U.S. District Court for the Eastern District of Louisiana, recently ordered that new Xarelto lawsuits can be directly filed into the nationwide Xarelto MDL. This pretrial order filed on March 24 will make it unnecessary for attorneys to file new Xarelto bleeding clams in their local district to await eventual transferred to the Xarelto MDL based in Louisiana, thereby increasing efficiency and avoiding delays related to transferring cases.

The Xarelto MDL is In re: Xarelto (Rivaroxaban) Products Liability Litigation, MDL No. 2592 U.S. District Court, Eastern District of Louisiana.

Overview of Xarelto Allegations

The Xarelto lawsuits pending in the Louisiana MDL are filed on behalf of men and women who allege that they experienced a serious internal bleeding episode like pulmonary bleeding, gastrointestinal bleeding, or deep vein thrombosis as a result of being prescribed Xarelto. In some instances, Xarelto lawsuits are filed on behalf of survivors whose loved ones have died allegedly due to Xarelto bleeding.

The Xarelto bleeding lawsuits name as defendants Bayer Healthcare Pharmaceuticals and Johnson & Johnson’s Janssen Pharmaceuticals unit, which are responsible for manufacturing and marketing the blood thinner. The Xarelto complaints accuse Bayer and Janssen of failing to warn consumers that Xarelto does not have an antidote, leaving doctors without any effective means to treat and stabilize patients who experienced uncontrolled and excessive bleeding.

Xarelto Bleeding Complications

Xarelto (rivaroxaban) is an oral blood thinner approved by the U.S. Food and Drug Administration (FDA) to treat deep vein thrombosis and pulmonary embolism and to reduce the risk of stroke and blood clots in patients with atrial fibrillation. Xarelto is considered a new generation blood thinner compared to Warfarin (Coumadin), a blood thinner that received FDA approval 60 years ago. However, unlike Warfarin, no antidotes are currently available to reverse the blood thinning properties of Xarelto, leaving doctors unable to reverse bleeding in an emergency.

Xarelto Lawsuits

As Xarelto lawyers continue to lay the groundwork for the Xarelto MDL, the number of Xarelto lawsuits filed against the makers of the drug continues to grow, as the number of Xarelto lawsuits has tripled this February. All these Xarelto bleeding cases claim similar incidents of severe bleeding problems. Bayer Healthcare and Janssen Pharmaceuticals now face at least 300 Xarelto injury claims with more than a thousand claims expected to be filed against the company by trial time. All claimants are expected to bring forth similar allegations that the company failed to warn them of the serious, and sometimes deadly, Xarelto side effects.

Men and women across the country who experienced uncontrollable bleeding, deep vein thrombosis, pulmonary embolism, stroke and other side effects allegedly as a result of using Xarelto and other prescription blood thinners may be able to obtain compensation for their suffering through a Xarelto lawsuit.